Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications.
In July 2010, Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of LOVENOX® (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily Glatopa® 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONE® 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRA® (adalimumab), a biosimilar version of ORENCIA® (abatacept) and a portfolio of five other early stage biosimilar programs in collaboration with Mylan and three novel drug candidates for autoimmune indications.
May 25, 2019
Copyright West LLC. Minimum 15 minutes delayed.
Events & Presentations
May 2, 2019 at 8:30 AM EDT
Momenta Pharmaceuticals First Quarter 2019 Earnings Call
Apr 2, 2019 at 12:00 PM EDT
Improved Fc-mediated Effector Functions By An Anti-CTLA-4 Multivalent Fc Agent
Mar 31, 2019 at 5:00 PM EDT
Discovery of a Potential Best-in-Class Anti-CD38 Therapeutic Utilizing Fc Multimerization (Session PO.IM02.16 – Therapeutic Antibodies 1, Abstract 561/25)